Please wait while the formulary information is being retrieved.
ERIVEDGE (VISMODEGIB)
- Basal cell carcinoma of skin
150 mg capsule
- 1 capsule (150 mg) by oral route once daily swallowing whole. Donot open or crush.
Basal cell carcinoma of skin
- 1 capsule (150 mg) by oral route once daily swallowing whole. Donot open or crush.
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactating mother
Contraindicated
- Pregnancy
Severe
Moderate
- None
ERIVEDGE (VISMODEGIB)
- Basal cell carcinoma of skin
- None
- Alopecia
- Anorexia
- Arthralgias
- Constipation
- Diarrhea
- Dysgeusia
- Fatigue
- Loss of taste
- Muscle spasm
- Nausea
- Vomiting
- Weight loss
More Frequent
Severe
Less Severe
- Azotemia
- Hypokalemia
- Hyponatremia
- Amenorrhea
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Hepatitis
- Premature epiphyseal closure
Less Severe
- None
Contraindicated
None
Severe Precaution
Vismodegib
Risk of premature epiphyseal fusion, including post discontinuation. Potential risk for other bone and dental abnormality.
- 1 Day – 18 Years
- Risk of premature epiphyseal fusion, including post discontinuation. Potential risk for other bone and dental abnormality.
Management or Monitoring Precaution
None
Vismodegib
- Severity Level:
D
- Additional Notes: Potential for embryotoxicity/embryolethality based on mechanism of action.
Contraindicated
Vismodegib
Potential for serious adv effects
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Potential for serious adv effects |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- Vismodegib must not be used during pregnancy because it may cause serious harm (possibly death) to an unborn baby. Women of childbearing age must have a negative pregnancy test within 7 days before starting this medication. They must also use a reliable form of birth control before starting vismodegib, while taking it, and for 2 years after the last dose of vismodegib.<br /><br /> Vismodegib passes into semen. Men taking vismodegib, even men who have had a vasectomy, must use condoms with spermicide during sex with women who are pregnant or of childbearing age, both during treatment with vismodegib and for 3 months after the last dose of this medication. Men should also not donate sperm during this time. If you or your partner become pregnant or think you may be pregnant, tell your doctor right away.
| Basal cell carcinoma of skin | |
| C44.01 | Basal cell carcinoma of skin of lip |
| C44.11 | Basal cell carcinoma of skin of eyelid, including canthus |
| C44.111 | Basal cell carcinoma of skin of unspecified eyelid, including canthus |
| C44.112 | Basal cell carcinoma of skin of right eyelid, including canthus |
| C44.1121 | Basal cell carcinoma of skin of right upper eyelid, including canthus |
| C44.1122 | Basal cell carcinoma of skin of right lower eyelid, including canthus |
| C44.119 | Basal cell carcinoma of skin of left eyelid, including canthus |
| C44.1191 | Basal cell carcinoma of skin of left upper eyelid, including canthus |
| C44.1192 | Basal cell carcinoma of skin of left lower eyelid, including canthus |
| C44.21 | Basal cell carcinoma of skin of ear and external auricular canal |
| C44.211 | Basal cell carcinoma of skin of unspecified ear and external auricular canal |
| C44.212 | Basal cell carcinoma of skin of right ear and external auricular canal |
| C44.219 | Basal cell carcinoma of skin of left ear and external auricular canal |
| C44.31 | Basal cell carcinoma of skin of other and unspecified parts of face |
| C44.310 | Basal cell carcinoma of skin of unspecified parts of face |
| C44.311 | Basal cell carcinoma of skin of nose |
| C44.319 | Basal cell carcinoma of skin of other parts of face |
| C44.41 | Basal cell carcinoma of skin of scalp and neck |
| C44.51 | Basal cell carcinoma of skin of trunk |
| C44.510 | Basal cell carcinoma of anal skin |
| C44.511 | Basal cell carcinoma of skin of breast |
| C44.519 | Basal cell carcinoma of skin of other part of trunk |
| C44.61 | Basal cell carcinoma of skin of upper limb, including shoulder |
| C44.611 | Basal cell carcinoma of skin of unspecified upper limb, including shoulder |
| C44.612 | Basal cell carcinoma of skin of right upper limb, including shoulder |
| C44.619 | Basal cell carcinoma of skin of left upper limb, including shoulder |
| C44.71 | Basal cell carcinoma of skin of lower limb, including hip |
| C44.711 | Basal cell carcinoma of skin of unspecified lower limb, including hip |
| C44.712 | Basal cell carcinoma of skin of right lower limb, including hip |
| C44.719 | Basal cell carcinoma of skin of left lower limb, including hip |
| C44.81 | Basal cell carcinoma of overlapping sites of skin |
| C44.91 | Basal cell carcinoma of skin, unspecified |
| 0-9 | A-Z |
|---|---|
| C44.01 | Basal cell carcinoma of skin of lip |
| C44.11 | Basal cell carcinoma of skin of eyelid, including canthus |
| C44.111 | Basal cell carcinoma of skin of unspecified eyelid, including canthus |
| C44.112 | Basal cell carcinoma of skin of right eyelid, including canthus |
| C44.1121 | Basal cell carcinoma of skin of right upper eyelid, including canthus |
| C44.1122 | Basal cell carcinoma of skin of right lower eyelid, including canthus |
| C44.119 | Basal cell carcinoma of skin of left eyelid, including canthus |
| C44.1191 | Basal cell carcinoma of skin of left upper eyelid, including canthus |
| C44.1192 | Basal cell carcinoma of skin of left lower eyelid, including canthus |
| C44.21 | Basal cell carcinoma of skin of ear and external auricular canal |
| C44.211 | Basal cell carcinoma of skin of unspecified ear and external auricular canal |
| C44.212 | Basal cell carcinoma of skin of right ear and external auricular canal |
| C44.219 | Basal cell carcinoma of skin of left ear and external auricular canal |
| C44.31 | Basal cell carcinoma of skin of other and unspecified parts of face |
| C44.310 | Basal cell carcinoma of skin of unspecified parts of face |
| C44.311 | Basal cell carcinoma of skin of nose |
| C44.319 | Basal cell carcinoma of skin of other parts of face |
| C44.41 | Basal cell carcinoma of skin of scalp and neck |
| C44.51 | Basal cell carcinoma of skin of trunk |
| C44.510 | Basal cell carcinoma of anal skin |
| C44.511 | Basal cell carcinoma of skin of breast |
| C44.519 | Basal cell carcinoma of skin of other part of trunk |
| C44.61 | Basal cell carcinoma of skin of upper limb, including shoulder |
| C44.611 | Basal cell carcinoma of skin of unspecified upper limb, including shoulder |
| C44.612 | Basal cell carcinoma of skin of right upper limb, including shoulder |
| C44.619 | Basal cell carcinoma of skin of left upper limb, including shoulder |
| C44.71 | Basal cell carcinoma of skin of lower limb, including hip |
| C44.711 | Basal cell carcinoma of skin of unspecified lower limb, including hip |
| C44.712 | Basal cell carcinoma of skin of right lower limb, including hip |
| C44.719 | Basal cell carcinoma of skin of left lower limb, including hip |
| C44.81 | Basal cell carcinoma of overlapping sites of skin |
| C44.91 | Basal cell carcinoma of skin, unspecified |
Formulary Reference Tool